Clinical trials: Human Immunodeficiency Virus I Infection
HIV, Empowerment
Empowerment Intervention for Young Women - Phase I
This study will begin to develop a culturally appropriate secondary prevention intervention for young HIV+ women through focus groups.
- Conditions
- HIV, Empowerment, HIV Infections
- Trial name
- NCT00891358
- Testing
- Prevention Empowerment Intervention for Young Women
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of North Carolina, Chapel Hill
Infection, Human Immunodeficiency Virus, HIV Infections
A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir
This study will be conducted in two Parts to confirm the acceptability/selection of a tablet formulation for future clinical development of GSK2838232.
- Trial name
- NCT03234036
- Testing
- GSK2838232 100 mg tablet, GSK2838232 50 mg capsule, Ritonavir 100 mg tablets
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV-1 Infection
Probiotic Visbiome for Inflammation and Translocation in HIV Ι
Modern antiretroviral therapy (ART) has transformed the clinical care and lived experience of HIV infection. However, increased rates of adverse health conditions that are related to immune activation, such as cardiovascular…
- Trial name
- PROOV IT I (NCT02441244)
- Testing
- Visbiome
- Where
- 2 sites in Canada
- Volunteers
- 1 people
- Sponsor
- University Health Network, Toronto
HIV Infections
A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)
To determine the safety and tolerance of various combinations of zidovudine (AZT) and didanosine (ddI) administered concurrently. To determine the pharmacokinetics of concurrent AZT and ddI administered orally.
- Trial name
- NCT00002014
- Testing
- Zidovudine, Didanosine
- Where
- 4 sites in United States
- Sponsor
- Glaxo Wellcome
Latent Tuberculosis Bacteriology and Histology Unknown, Latent Tuberculosis
A Phase I/IIa AERAS-456 in HIV-Negative Adults With & Without Latent Tuberculosis Infection (C-035-456)
This is a Phase I/IIa, double-blind, randomized, placebo-controlled, dose- and regimen-finding study in healthy adults with and without LTBI, who are BCG-vaccinated, HIV negative, and have no history or evidence of TB disease.
- Trial name
- NCT01865487
- Testing
- H56ug/IC31nmol
- Where
- 2 sites in South Africa
- Volunteers
- 98 people
- Sponsor
- Aeras
HIV-1 Infection
Novel Interventions in HIV-1 Infection
For several years there has been interest in why some people with HIV-1 progress more slowly to disease and have longer survival without Highly Active Antiretroviral Therapy (HAART) than others.
- Trial name
- IMIRC1003 (NCT01130376)
- Testing
- GTU-MultiHIV B clade vaccine1mg, Interleukin-2, GM-CSF
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Imperial College London
HIV Infections
Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent
Dolutegravir (DTG), a human immunodeficiency virus (HIV)-1 integrase inhibitor (INI), and Rilpivirine (RPV), a non-nucleoside HIV-1 reverse transcriptase inhibitor (NNRTI), are each approved in the United States (US), European…
- Trial name
- NCT03984838
- Testing
- JULUCA (Dolutegravir and Rilpivirine) 50mg/25mg FDC tablet
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Cytomegalovirus Infections, HIV Infections
A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria
To determine the safety, tolerance, and potential in vivo antiviral effects of five dosage levels and a dose to be determined of human anti-cytomegalovirus (CMV) monoclonal antibody (SDZ MSL-109; formerly SDZ 89-109) when…
- Trial name
- NCT00002268
- Testing
- Sevirumab
- Where
- 2 sites in United States
- Sponsor
- Sandoz
HIV Infection
A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals
BCN03 is a Single-site, randomized, double-blind, placebo-controlled, phase I study to evaluate the safety, tolerability, immunogenicity, and efficacy of a vaccine regimen that includes a sequence of the T- and B-cell immunogens…
- Trial name
- NCT05208125
- Testing
- ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS)., Normal saline solution
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- IrsiCaixa
Hepatitis C Infection, HIV Infection
A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination
This study is aimed at assessing the safety of candidate Hepatitis C vaccines AdCh3NSmut/MVA-NSmut and HIV vaccines ChAdV63.HIVconsv/MVA.HIVconsv when administered separately or in combination to healthy volunteers.
- Trial name
- NCT02362217
- Testing
- AdCh3NSmut1, MVA-NSmut, ChAdV63.HIVconsv
- Where
- United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- University of Oxford
HIV Infections
Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients
The purpose of this study is to assess the safety of GX-12 gene therapy combined with HAART in the HIV-1 infected patients and to investigate the efficacy with the value of plasma viral load and with CD4 counts and HIV-1 specific…
- Trial name
- NCT00517569
- Testing
- GX-12, HAART
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Genexine, Inc.
HIV Infection
Safety and Efficacy Study of Etanercept (Enbrel) on the Response Rate of HIV-infected Subjects
The purpose of conducting this already-FDA approved Phase I clinical trial is to evaluate the safety and efficacy of etanercept (Enbrel) on the response rate in HIV-infected subjects who have failed to respond to conventional…
- Trial name
- NCT00091741
- Testing
- Etanercept (Enbrel)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Georgetown University
HIV Infection
Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir
The purpose of this study is to compare the safety, tolerability and efficacy of a regimen containing once-daily elvitegravir (EVG) versus twice-daily raltegravir (RAL) added to a background regimen (1 fully-active ritonavir…
- Trial name
- NCT00708162
- Testing
- Elvitegravir, Raltegravir, Background regimen
- Where
- 180 sites in United States, Australia and 12 more
- Volunteers
- 724 people
- Sponsor
- Gilead Sciences
HIV-1-infection, Hiv
Studying Topiramate for Re-Activating the HIV-1 Reservoir
Even with current HIV treatments, HIV is still a lifelong disease because it hides in some long-lasting cells in the body. One of the strategies to find a cure for HIV works by finding the virus in these cells, making it visible…
- Conditions
- HIV-1-infection, Hiv, HIV Infections, HIV I Infection
- Trial name
- STAR (NCT06282783)
- Testing
- Topiramate
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Erasmus Medical Center
Human Immunodeficiency Virus
Evaluation of Safety and Immunogenicity of Ad26.Mos4.HIV and CH505 TF chTrimer Combination in Healthy Adults
This is a Phase I, randomized, double-blind, placebo-controlled clinical study to define the safety and immunogenicity resulting from a rapid dose-escalating vaccination schedule as compared to that of a co-administered…
- Trial name
- RV591 (NCT06205056)
- Testing
- Ad26.Mos4.HIV in CH505 TF chTrimer + ALFQ [Arm 1a], CH505 TF chTrimer + ALFQ [Arm 1a], Ad26.Mos4.HIV in CH505 TF chTrimer +ALFQ [Arm 2a]
- Where
- Uganda
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
HIV Infection
Phase I Study to Evaluate the Safety and Immunogenicity of HIV-1 Immunogen in Children With HIV-1 Infection
This is a single dose, phase I study to evaluate the safety/tolerance and the immunogenicity of HIV-1 Immunogen, gp120-depleted inactivated HIV-1 preparation in Incomplete Freund's Adjuvant (IFA), in children with HIV-1…
- Trial name
- NCT00001445
- Testing
- HIV-1 Immunogen
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
HIV - Human Immunodeficiency Virus, Insomnia Disorder
A Sleep Program to Improve Sleep Quality in People With HIV
Sleep problems, such as insomnia, are more frequent and intense in individuals living with HIV. These sleep difficulties can increase the difficulties in thinking and concentrating.
- Trial name
- NCT02571595
- Testing
- Digital cognitive behavioural therapy for insomnia (dCBT-I)
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- McGill University
HIV I Infection, HIV-2 Infection
Access HIV Ag/Ab Combo Assay - European Union (EU) Clinical Trial Protocol
The objective of this study is the collection and testing of clinical samples to determine the clinical performance of the Access HIV Ag/Ab Combo assay on the DxI 9000 Access Immunoassay Analyzer
- Trial name
- HIV-EU-11-18 (NCT04971343)
- Testing
- Access HIV_blood donor, Access HIV_Hospitalized patient, Access HIV_known HIV-1 antibody positives
- Where
- 6 sites in France
- Volunteers
- 8,650 people
- Sponsor
- Beckman Coulter, Inc.
HIV
Phase I Study of HIV 1 Antigen Expanded Specific T Cell Therapy
This is a phase 1, single-site study is to evaluate the safety and immunologic and virologic efficacy of ex vivo expanded HIV-1 multi-antigen specific T-cell (HXTC) therapy in HIV-infected individuals with viral suppression on…
- Trial name
- HXTC (NCT02208167)
- Testing
- HXTC infusion
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infection
A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)
This Phase I study was directed at evaluating the safety profile and the immunogenicity of the vaccination with recombinant HIV-1 Tat and V2-deleted Env (delta-V2 Env) proteins administered in association in healthy…
- Trial name
- NCT01441193
- Testing
- HIV-1 Tat/delta-V2 Env combined vaccine, HIV-1 delta-V2 Env vaccine, HIV-1 Tat vaccine 7.5 microg
- Where
- 3 sites in Italy
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Barbara Ensoli, MD